Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

Disparities in MCS Use for STEMI-Related Shock Seen Across the US

News Daily News

Disparities in MCS Use for STEMI-Related Shock Seen Across the US

October 21, 2025

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

News Daily News

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Michael O'Riordan

June 14, 2023

Shifting Acute MI Outcomes by Medicare Type: A Window Into Insurer’s Influence

News Daily News

Shifting Acute MI Outcomes by Medicare Type: A Window Into Insurer’s Influence

December 09, 2022

January 2021 News Roundup

News Opinion CV Team Dispatch

January 2021 News Roundup

January 01, 2021

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.